Roche extends Spark offer again as regulatory review drags on
[ZURICH] Roche extended its offer to buy Spark Therapeutics on Monday, this time until Oct 30, as US and British regulators continue to scrutinize the Swiss drugmaker's US$4.3 billion oft-delayed bid to swallow the US gene therapy specialist.
The terms and conditions remain unchanged for the deal, which analysts have said may be hung up on competition concerns over what a combination would mean for the very competitive market for hemophilia A treatments. Roche has declined to comment on what is holding back the US Federal Trade Commission from signing off on the transaction.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action
France's Casino supermarket chain to axe up to 3,200 jobs